Condition
Metabolic-associated Fatty Liver Disease
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 4 (1)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07185932Early Phase 1RecruitingPrimary
Efficacy and Safety of Rifaximin in Treating MAFLD
NCT07149571Recruiting
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
NCT05140694Phase 4UnknownPrimary
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Showing all 3 trials